Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults
Status:
Completed
Trial end date:
2022-02-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetics and safety of SVG101
(dispersible tab. of everolimus) in healthy volunteers compared to Afinitor tab. after oral
administration.